Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004